CalciMedica, Inc.(CALC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CALC Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for CalciMedica, Inc. (CALC), a Healthcare sector company. CALC is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), CalciMedica, Inc. reports net income of $-7.7M, free cash flow of $-4.6M. Top institutional holders of CALC by reported 13-F value include Woodline Partners, HEIGHTS CAPITAL MANAGEMENT, Squadron Capital Management, based on the most recent SEC filings. CALC trades on the Nasdaq exchange and files with the SEC under CIK 1534133. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CALC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CalciMedica, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-7.7M
Free Cash Flow
Q2 2026
$-4.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-115.8% YoYOperating Income
+4.5% YoYEPS (Diluted)
-61.5% YoYTotal Assets
-31.3% YoYOp. Cash Flow
-0.2% YoYFree Cash Flow
-0.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-29.6M -115.8% | $-13.7M +60.1% | $-34.4M -339.1% | $-7.8M +78.2% | $-35.8M -30.1% | $-27.5M |
| Operating Income | $-23.1M +4.5% | $-24.2M +36.4% | $-38.1M -168.3% | $-14.2M +60.5% | $-35.9M -20.5% | $-29.8M |
| EPS (Diluted) | $-1.97 -61.5% | $-1.22 +84.1% | $-7.66 +93.1% | $-111.16 -6477.5% | $-1.69 | — |
| Total Assets | $13.6M -31.3% | $19.8M +62.4% | $12.2M +263.8% | $3.3M -95.2% | $69.1M -32.1% | $101.8M |
| Operating Cash Flow | $-21.2M -0.2% | $-21.1M +17.8% | $-25.7M -118.8% | $-11.8M +62.7% | $-31.5M +1.8% | $-32.1M |
| Free Cash Flow | $-21.2M -0.2% | $-21.2M +18.0% | $-25.8M -119.4% | $-11.8M +63.2% | $-32.0M +3.3% | $-33.1M |
Get alerted when CALC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CalciMedica, Inc. including:
Top Institutional Holders of CALC
Woodline Partners LP
$2.6M2,489,729 shHEIGHTS CAPITAL MANAGEMENT, INC
$1.6M1,556,081 shSquadron Capital Management LLC
$1.3M1,244,864 shStonepine Capital Management, LLC
$1.3M2,128,597 shStemPoint Capital LP
$1.2M1,244,864 shL1 Global Manager Pty Ltd
$256.4K248,972 shMORGAN STANLEY
$147.5K143,245 shGEODE CAPITAL MANAGEMENT, LLC
$113.8K110,477 shRENAISSANCE TECHNOLOGIES LLC
$100.2K97,300 shVANGUARD CAPITAL MANAGEMENT LLC
$91.6K88,956 sh
| Fund | Value | Shares |
|---|---|---|
| Woodline Partners LP | $2.6M | 2,489,729 |
| HEIGHTS CAPITAL MANAGEMENT, INC | $1.6M | 1,556,081 |
| Squadron Capital Management LLC | $1.3M | 1,244,864 |
| Stonepine Capital Management, LLC | $1.3M | 2,128,597 |
| StemPoint Capital LP | $1.2M | 1,244,864 |
| L1 Global Manager Pty Ltd | $256.4K | 248,972 |
| MORGAN STANLEY | $147.5K | 143,245 |
| GEODE CAPITAL MANAGEMENT, LLC | $113.8K | 110,477 |
| RENAISSANCE TECHNOLOGIES LLC | $100.2K | 97,300 |
| VANGUARD CAPITAL MANAGEMENT LLC | $91.6K | 88,956 |
More Healthcare Companies
View all Healthcare →Put CALC on your watchlist
Track score changes the day CalciMedica, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CALC a good stock to buy?
13F Pro's AI-powered analysis of CalciMedica, Inc. (CALC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CALC are available on the CALC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CALC is classified as a small company.
Which hedge funds own CALC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CALC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CalciMedica, Inc.'s investment landscape.